Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9896517 | 0.87 | PTGS1 (0.57) | PTPN1PTGS1PTGS2PPARAPPARD | |
| SCHEMBL6005803 | 0.82 | PPARA (0.50) | PTPN1PTGS1PTGS2PPARAPPARD | |
| SCHEMBL8873187 | 0.81 | SLC1A1 (0.56) | PTGS1PTGS2PPARAPPARDPPARG | |
| SCHEMBL4664796 | 0.80 | PPARA (0.56) | PTPN1PTGS1PTGS2PPARAPPARD | |
| SCHEMBL4610922 | 0.79 | P4HTM (0.52) | PTPN1PTGS1PTGS2PPARAPPARG | |
| SCHEMBL12627633 | 0.79 | CPB2 (0.39) | PTPN1CPA1DPP4PIN1 | |
| SCHEMBL5813461 | 0.78 | LDHA (0.51) | PTGS1PTGS2PPARAPPARGDPP4 | |
| SCHEMBL27525650 | 0.76 | CHRM1 (0.47) | PTPN1PTGS1PTGS2PPARAPPARD | |
| SCHEMBL29174149 | 0.76 | LDHA (0.59) | PTGS1PTGS2PPARAPPARDPPARG | |
| SCHEMBL7230282 | 0.75 | KDM6B (0.61) | PPARAPPARGDPP4PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105509-B2 | Benzodiazepine derivatives as APP modulators | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | MERCK SHARPE & DOHME LIMITED (GB) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | BACE1, PSEN1, APP | PTPN1 4178/4885PTGS1 650/4885PTGS2 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.